Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: May 04, 2022
Accepted: August 23, 2022
Published online: October 10, 2022

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 5

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Introduction: Online hemodiafiltration (OL-HDF) and hemodialysis (HD) using high-performance membranes such as adsorptive, medium cut-off (MCO), and super high-flux (SHF) dialyzers have been implemented to enhance the removal of middle molecules (MM). The aim of this study was to compare the efficacy of different dialysis strategies and dialyzers on small solutes and MM reduction ratio (RR) and mass removal. Methods: We performed a prospective study in 8 HD patients. Each patient underwent 9 dialysis sessions: seven sessions on HD using either Theranova 500™, Elisio 21H™, Renak PS-2.0W™, Filtryzer BK-2.1F™, Vie 21X™, TS-2.1UL™ or FDY 210-GW™ dialyzers and two sessions on OL-HDF using Elisio 21H™ or Renak PS-2.0W™ dialyzers. Results: Urea mass removal and RR were similar between all dialysis strategies. The lowest beta2-microglobulin RR was achieved with Filtryzer BK-2.1F™ HD (p < 0.05). Compared to Elisio 21H™ HD, Renak PS-2.0W™ OL-HDF produced higher beta2-microglobulin mass removal (181 ± 46 vs. 317 ± 161 mg, p < 0.05). Theranova 500™ HD, Vie 21X™ HD, FDY 210-GW™ HD, Elisio 21H™ OL-HDF, and Renak PS-2.0W™ OL-HDF induced higher RR for kappa and lambda FLC, as compared to Elisio 21H™ HD and Filtryzer BK-2.1F™ HD (p < 0.05). Renak PS-2.0W™ OL-HDF achieved higher kappa FLC mass removal compared to Elisio 21H™ HD (563 ± 515 vs. 141 ± 47 mg, p < 0.01) and to Renak PS-2.0W™ HD (563 ± 515 vs. 153 ± 25 mg, p < 0.05). Albumin loss varied from 0.02 ± 0.05 to 7.6 ± 3.8 g/session with Elisio 21H™ HD and Renak PS-2.0W™ OL-HDF, respectively. Compared to all other strategies, Renak PS-2.0W™ OL-HDF induced a significantly higher albumin loss (p < 0.05). Conclusion: This study confirms that albumin loss and removal of MM are similar using conventional Elisio 21H™ OL-HDF, MCO-HD, and SHF type V dialyzers. Although Renak PS-2.0W™ OL-HDF provides high performance for MM depuration, this protein-permeable dialyzer should not be used in OL-HDF because of excessive albumin loss.

© 2022 S. Karger AG, Basel

References Rosner MH, Reis T, Husain-Syed F, Vanholder R, Hutchison C, Stenvinkel P, et al. Classification of uremic toxins and their role in kidney failure. Clin J Am Soc Nephrol. 2021 Jul;16(12):1918–28. Wolley M, Jardine M, Hutchison CA. Exploring the clinical relevance of providing increased removal of large middle molecules. Clin J Am Soc Nephrol. 2018 May;13(5):805–14. Desjardins L, Liabeuf S, Lenglet A, Lemke HD, Vanholder R, Choukroun G, et al. Association between free light chain levels, and disease progression and mortality in chronic kidney disease. Toxins. 2013 Nov;5(11):2058–73. Abe M, Hamano T, Wada A, Nakai S, Masakane I; Renal Data Registry Committee, Japanese Society for Dialysis Therapy. Effect of dialyzer membrane materials on survival in chronic hemodialysis patients: results from the annual survey of the Japanese Nationwide Dialysis Registry. PLoS One. 2017 Sep;12(9):e0184424. Abe M, Masakane I, Wada A, Nakai S, Nitta K, Nakamoto H. Dialyzer classification and mortality in hemodialysis patients: a 3-year Nationwide Cohort Study. Front Med. 2021Aug;8:740461. Ronco C, Cruz D. Hemodiafiltration history, technology, and clinical results. Adv Chronic Kidney Dis. 2007 Jul;14(3):231–43. Fujimori A. Clinical comparison of super high-flux HD and on-line HDF. Blood Purif. 2013 Feb;35(Suppl 1):81–4. Thammathiwat T, Tiranathanagul K, Limjariyakul M, Chariyavilaskul P, Takkavatakarn K, Susantitaphong P, et al. Super high-flux hemodialysis provides comparable effectiveness with high-volume postdilution online hemodiafiltration in removing protein-bound and middle-molecule uremic toxins: a prospective cross-over randomized controlled trial. Ther Apher Dial. 2021 Feb;25(1):73–81. Maduell F, Rodas L, Broseta JJ, Gomez M, Xipell M, Guillen E, et al. Medium cut-off dialyzer versus eight hemodiafiltration dialyzers: comparison using a global removal score. Blood Purif. 2019;48(2):167–74. Maduell F, Rodas L, Broseta JJ, Gomez M, Xipell Font M, Molina A, et al. High-permeability alternatives to current dialyzers performing both high-flux hemodialysis and postdilution online hemodiafiltration. Artif Organs. 2019 Oct;43(10):1014–21. Potier J, Queffeulou G, Bouet J. Are all dialyzers compatible with the convective volumes suggested for postdilution online hemodiafiltration? Int J Artif Organs. 2016 Nov;39(9):460–70. Ronco C. The rise of expanded hemodialysis. Blood Purif. 2017;44(2):I–VIII. Lorenzin A, Neri M, Clark WR, Garzotto F, Brendolan A, Nalesso F, et al. Modelingof internal filtration in theranova hemodialyzers. Contrib Nephrol. 2017;191:127–41. Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017 Jan;32(1):165–72. Belmouaz M, Bauwens M, Hauet T, Bossard V, Jamet P, Joly F, et al. Comparison of the removal of uremic toxins with medium cut-off and high-flux dialyzers: a randomized clinical trial. Nephrol Dial Transplant. 2020 Feb;35(2):328–35. Sevinc M, Hasbal NB, Yilmaz V, Basturk T, Ahbap E, Sakaci T, et al. Comparison of circulating levels of uremic toxins in hemodialysis patients treated with medium cut-off membranes and high-flux membranes: Theranova in Sisli Hamidiye Etfal (THE SHE) randomized control study. Blood Purif. 2020;49(6):733–42. Belmouaz M, Diolez J, Bauwens M, Duthe F, Ecotiere L, Desport E, et al. Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle-sized molecules. Clin Nephrol. 2018 Jan;89 (2018)(1):50–6. Ciceri P, Cozzolino M. Expanded haemodialysis as a current strategy to remove uremic toxins. Toxins. 2021 May;13(6):380. Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol. 2005 Aug;16(8):2421–30. Ward RA, Beck W, Bernardo AA, Alves FC, Stenvinkel P, Lindholm B. Hypoalbuminemia: a price worth paying for improved dialytic removal of middle-molecular-weight uremic toxins? Nephrol Dial Transplant. 2019 Jun;34(6):901–7. Van Gelder MK, Abrahams AC, Joles JA, Kaysen GA, Gerritsen KGF. Albumin handling in different hemodialysis modalities. Nephrol Dial Transplant. 2018 Jun;33(6):906–13. Bergström J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis. Lancet. 1987 Mar;1(8533):628–9. Said N, Lau WJ, Ho YC, Lim SK, Zainol Abidin MN, Ismail AF. A review of commercial developments and recent laboratory research of dialyzers and membranes for hemodialysis application. Membranes. 2021 Oct;11(10):767. Aoike I. Clinical significance of protein adsorbable membranes: long-term clinical effects and analysis using a proteomic technique. Nephrol Dial Transplant. 2007 Jul;22(Suppl 5):13–9. Santoro A, Guadagni G. Dialysis membrane: from convection to adsorption. NDT Plus. 2010 May;3(suppl 1):i36–9. Grooteman MPC, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AHA, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol. 2012 Jun;23(6):1087–96. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant. 2013 Jan;28(1):192–202. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macia J, Carreras J, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013 Feb;24(3):487–97. Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, et al. Medium cut-off (MCO) membranes reduce inflammation in chronic dialysis patients-a randomized controlled clinical trial. PLoS One. 2017 Jan;12(1):e0169024. Hadad-Arrascue F, Nilsson L, Rivera AS, Bernardo AA, Cabezuelo Romero JB. Expanded hemodialysis as effective alternative to on-line hemodiafiltration: a randomized mid-term clinical trial. Ther Apher Dial. 2022 Feb;26(1):37–44. Article / Publication Details

First-Page Preview

Received: May 04, 2022
Accepted: August 23, 2022
Published online: October 10, 2022

Number of Print Pages: 9
Number of Figures: 3
Number of Tables: 5

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU